ChemLifeIntel/Companies/CinnaGen

CinnaGen

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 2 of 2 briefs on CinnaGen

CLINICAL & PIPELINE·Drug Approval

CinnaGen's Zandoriah®: First EU Authorization for Teriparatide Biosimilar in Osteoporosis Across 30 EEA States

CinnaGen has secured its first EU authorization for Zandoriah®, a Teriparatide biosimilar for osteoporosis, approved by the European Commission. This marks a significant market entry across 30 EEA states, leveraging CinnaGen's manufacturing investments. Decision-makers must assess new supply chain opportunities and competitive shifts in the European bone health market.

90-Day Activity

CinnaGenZandoriah

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

2h ago Drug Approval

MARKET INTELLIGENCE·M&A

CinnaGen's Zandoriah Secures EC Approval: Reshaping Teriparatide Biosimilar Access Across 30 EEA States

CinnaGen has secured European Commission approval for Zandoriah, its teriparatide biosimilar for osteoporosis, across all 30 EEA states. This pivotal regulatory milestone introduces a new, cost-effective treatment option, intensifying competition in the European osteoporosis market. Procurement directors must re-evaluate sourcing strategies, while regulatory affairs heads should note the EMA-compliant biosimilarity precedent. This approval signals significant shifts for supply chain and business development executives in the region.

90-Day Activity

CinnaGenZandoriah

RARobert Ashworth· Principal Intelligence Analyst

1d ago